Scarica l'app Stockscreener
0.888
1.11%
-0.01
Dopo l'orario di chiusura:
.95
0.062
+6.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.898
Aprire:
$0.91
Volume 24 ore:
1.13M
Relative Volume:
1.18
Capitalizzazione di mercato:
$62.50M
Reddito:
-
Utile/perdita netta:
$-37.34M
Rapporto P/E:
-0.5729
EPS:
-1.55
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
+1.82%
1M Prestazione:
-28.39%
6M Prestazione:
-23.45%
1 anno Prestazione:
-27.21%
Intervallo 1D:
$0.87
$0.9296
Intervallo di 1 settimana:
$0.8335
$0.98
Portata 52W:
$0.4986
$1.72
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Nome
Sellas Life Sciences Group Inc
Settore
Industria
Telefono
(646) 200-5278
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Confronta SLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
0.888 | 62.50M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Iniziato | Oppenheimer | Outperform |
| 2018-04-02 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-19 | Aggiornamento | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia - Marketscreener.com
SELLAS Life Sciences Advances Phase 3 AML Trial - TipRanks
SELLAS triggers interim analysis in AML trial - Investing.com
SELLAS triggers interim analysis in AML trial By Investing.com - Investing.com Canada
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewswire
SELLAS Life Sciences Hits Major Milestone in Phase 3 AML Cancer Treatment Trial - StockTitan
SELLAS reports promising AML drug trial results By Investing.com - Investing.com Canada
SELLAS reports promising AML drug trial results - Investing.com India
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - The Manila Times
SELLAS Announces Positive Overall Survival and Overall - GlobeNewswire
SELLAS' SLS009 Triples Survival Time in Phase 2 AML Trial, Shows Breakthrough Response Rates - StockTitan
Anson Funds Management LP Purchases Shares of 793,835 SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - MarketBeat
SELLAS announces data indicating key predictor of response to SLS009 in solid cancers - Yahoo Finance
SELLAS Announces Positive Data from Preclinical Studies - GlobeNewswire
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor - The Bakersfield Californian
SELLAS Life Sciences' SLS009 Shows 67% Efficacy in ASXL1-Mutated Cancer Study | SLS Stock News - StockTitan
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely - Simply Wall St
We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate - Yahoo Finance
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Reports 31% Response Rate in AML Trial, Narrows Q3 Loss to $7.1M | SLS Stock News - StockTitan
Highbridge Capital Management's Strategic Acquisition of SELLAS Life Sciences Shares - GuruFocus.com
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 - GlobeNewswire
Northrop Grumman Corp (NOC-N) QuotePress Release - The Globe and Mail
SELLAS' Cancer Drug Shows 50% Response Rate in Leukemia Trial, Doubles Survival Time | SLS Stock News - StockTitan
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest - MarketBeat
FDA grants rare pediatric disease designation to SELLAS cancer drug By Investing.com - Investing.com Australia
SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S - The Bakersfield Californian
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia - StockTitan
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Trading Day Triumph: SELLAS Life Sciences Group Inc (SLS) Ends at 1.19, a -2.46 Surge/Plunge - The Dwinnex
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
SELLAS extends Times Square lease through 2026 - Investing.com
SELLAS extends Times Square lease through 2026 By Investing.com - Investing.com Australia
What is SELLAS Life Sciences Group Inc (SLS) Stock Return on Shareholders’ Capital? - SETE News
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 0.8% - MarketBeat
Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech
Biotech Soars On Material Transfer Agreement - Invezz
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Lombard Odier Asset Management Europe Ltd Sells 15,000 Shares of StoneCo Ltd. (NASDAQ:STNE) - Defense World
Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug - XM
Steniel Manufacturing board clears share offering to raise up to P315m - manilastandard.net
How did SELLAS Life Sciences Group Inc (SLS) fare last session? - US Post News
SLM price target lowered to $26 from $29 at Wedbush - TipRanks
Setna iO announces new UK headquarters - AviTrader
Inspire Investing LLC Boosts Stake in Silicon Laboratories Inc. (NASDAQ:SLAB) - Defense World
Australia's Stelar Metals rises on copper, silver find - XM
Quarterly Metrics: Quick and Current Ratios for SELLAS Life Sciences Group Inc (SLS) - The Dwinnex
Investor’s Delight: ENDRA Life Sciences Inc (NDRA) Closes Weak at 0.20, Down -6.77 - The Dwinnex
Ready to Jump After Recent Trade: SELLAS Life Sciences Group Inc (SLS) - SETE News
Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):